


CLAIMS


1. An antibiotic, caprazamycin A, caprazamycin B, caprazamycin C, caprazamycin E or caprazamycin F, which is a compound represented by the following general formula

5 (I)




wherein R is tridecyl group for caprazamycin A; 11-methyl-dodecyl group for caprazamycin B; dodecyl group for caprazamycin C; undecyl group for caprazamycin E; and 9-methyl-decyl group for caprazamycin F, or a pharmaceutically acceptable salt thereof.

2. An antibiotic as claimed in Claim 1, which is caprazamycin A represented by the following formula (Ia)




that is, the compound of general formula (I) shown in
Claim 1 where R is tridecyl group $-(CH_2)_{12}-CH_3$.


3. An antibiotic as claimed in Claim 1, which is
15 caprazamycin B represented by the following formula (Ib)



that is, the compound of general formula (I) shown in
Claim 1 where R is 11-methyl-dodecyl group




4. An antibiotic as claimed in Claim 1, which is
 5 caprazamycin C represented by the following formula (Ic)




that is, the compound of general formula (I) shown in
 Claim 1 where R is dodecyl group $-(\text{CH}_2)_{11}\text{CH}_3$.

5. An antibiotic as claimed in Claim 1, which is
 20 caprazamycin E represented by the following formula (Ie)




that is, the compound of general formula (I) shown in
Claim 1 where R is undecyl group $-(\text{CH}_2)_{10}-\text{CH}_3$.

6. An antibiotic as claimed in Claim 1, which is
15 caprazamycin F represented by the following formula (If)



that is, the compound of general formula (I) shown in
Claim 1 where R is 9-methyl-decyl group



7. A process for the production of an antibiotic,
 5 caprazamycin A, caprazamycin B, caprazamycin C,
 caprazamycin E and/or caprazamycin F represented by the
 general formula (I) given in Claim 1, characterized in
 that the process comprises culturing a microbial strain
 which belongs to the genus Streptomyces and which is
 10 capable of producing at least one of caprazamycin A,
 caprazamycin B, caprazamycin C, caprazamycin E and
 caprazamycin F, and recovering at least one of
 caprazamycins A, B, C, E and F from the resulting culture.

8. A process as claimed in Claim 7, wherein as
 15 the microbial strain capable of producing at least one of
 caprazamycins A, B, C, E and F, there is used Streptomyces
 sp. MK730-62F2 which has been deposited in the National
 Institute of Bioscience and Human-Technology, Agency of
 Industrial Science and Technology, under the deposit
 20 number of "FERM BP-7218" in terms of the Budapest Treaty.

9. A pharmaceutical composition comprising as an
 active ingredient at least one of caprazamycins A, B, C, E
 and F having the general formula (I) given in Claim 1, or
 a salt thereof, in admixture with a pharmaceutically
 25 acceptable carrier or carriers.

10. A composition as claimed in Claim 9, which is
 an antibacterial composition.

11. As a novel microorganism, Streptomyces sp.

MK730-62F2 which has a characteristic nature that it is capable of producing caprazamycins A, B, C, E and F having the general formula (I) given in Claim 1, and which has been deposited in the National Institute of Bioscience and
5 Human-Technology, Agency of Industrial Science and Technology, under the deposit number of "FERM BP-7218".

10

15

20

25